Journal of Psychopharmacology最新文献

{"title":"Mismatch negativity in patients with bipolar affective disorder: a systematic review and meta-analysis.","authors":"Alice Caulfield, Rita Moura, Stefan Brugger, Allan H Young, Mitul A Mehta, Rick A Adams, Katherine Beck","doi":"10.1177/02698811261436604","DOIUrl":"https://doi.org/10.1177/02698811261436604","url":null,"abstract":"<p><strong>Introduction: </strong>Mismatch negativity (MMN) is a neural response to unexpected deviations from a regular sequence of stimuli. A diminished MMN is highly replicated in schizophrenia; however, whether this is observed in bipolar disorder (BD) is less clear.</p><p><strong>Aim: </strong>To conduct a meta-analysis of MMN alterations in people with BD compared to healthy controls.</p><p><strong>Methods: </strong>Electronic databases were searched until 20/10/2025, for between-subjects studies examining MMN amplitudes and or latencies in BD patients compared with controls. 15 studies consisting of 437 BD patients and 815 controls were included in this analysis.</p><p><strong>Results: </strong>The primary outcome was the difference in MMN amplitude between the BD and control groups, from studies using standard MMN paradigms. Meta-analysis revealed diminished MMN amplitudes (<i>n</i> = 14) in BD versus controls (standardised mean difference = 0.47, 95% confidence interval [0.28, 0.66], <i>p</i> < 0.0001). Exploratory secondary meta-regressions revealed no significant relationship between MMN amplitude and age, sex, symptoms, or illness duration. Subgroup analyses revealed MMN amplitude group difference for paradigms using duration versus frequency deviants.</p><p><strong>Conclusion: </strong>MMN amplitude deficits are observed in bipolar disorder. As MMN deficits are consistently observed in schizophrenia, whether the MMN deficits observed in BD relate to psychotic symptoms or specific BD subtypes remains unclear. Limitations of this meta-analysis include low study numbers for some of the meta-regressions. Most included studies did not separate bipolar subtypes; therefore, it was not possible to determine whether the observed effects relate to affective or psychotic symptoms. Future research should distinguish putative BD subtypes and include measures of symptoms to clarify the potential of MMN as a clinical marker to guide treatment decisions.</p>","PeriodicalId":16892,"journal":{"name":"Journal of Psychopharmacology","volume":" ","pages":"2698811261436604"},"PeriodicalIF":5.5,"publicationDate":"2026-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147690745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Substance use predictors of arrest and self-reported criminal behavior in the United States: The role of psychedelics and rarely used drugs.","authors":"Jesse J Norris","doi":"10.1177/02698811261436577","DOIUrl":"https://doi.org/10.1177/02698811261436577","url":null,"abstract":"<p><strong>Background: </strong>Little research investigates the role of rarely used drugs in criminal offending. Moreover, given research suggesting that psychedelics reduce criminal offending, more research is needed to further document connections between psychedelics and crime.</p><p><strong>Aim: </strong>This study examines the role of rarely used drugs in criminal behavior and extends previous research on psychedelics by incorporating additional substance use measures, including youth respondents, and analyzing self-reported crime as well as arrests.</p><p><strong>Methods: </strong>Using data from the National Survey on Drug Use and Health (2014-2023) (<i>n</i> = 544,740), a nationally representative US survey, logistic regressions were performed testing whether substance use measures predicted arrest for various offenses and self-reported crimes after controlling for multiple covariates.</p><p><strong>Results: </strong>Use of phencyclidine (PCP), a rarely used drug, was strongly associated with arrest for serious violent offenses, assault, and sex offenses, and with attacking three or more people. Another rarely used substance, gamma-hydroxybutyrate (GHB), was associated with arrest for several offenses. Among psychedelics, psilocybin was associated with reduced odds of several offenses, while DMT/AMT/Foxy and peyote were associated with increased odds. LSD and <i>Salvia divinorum</i> were associated with increased odds of some offenses but decreased odds of others. For minors, psychedelics were mainly associated with increased odds of arrest, as protective effects were almost entirely absent. Psychedelics were associated with reduced odds of arrest for whites far more than for minorities.</p><p><strong>Conclusions: </strong>PCP use was strongly associated with violent offending. This study's mixed findings on psychedelics indicate a need for further research to clarify causal connections between psychedelics and crime-related outcomes.</p>","PeriodicalId":16892,"journal":{"name":"Journal of Psychopharmacology","volume":" ","pages":"2698811261436577"},"PeriodicalIF":5.5,"publicationDate":"2026-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147690817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of N, N-dimethyltryptamine (DMT) psychedelic therapy for substance misuse: A systematic review and meta-analysis.","authors":"Lisa M Wallace, Andrea Bujor, Gustavo Sudre, Mark Kennedy, Diana-Elena Bahnareanu, Khushi Mittal","doi":"10.1177/02698811261430518","DOIUrl":"https://doi.org/10.1177/02698811261430518","url":null,"abstract":"<p><strong>Background: </strong>Conventional psychological and pharmacological substance abuse treatments are limited to moderate effect sizes and fail to magnify outcomes when combined. Analog psychedelic agents N, N-dimethyltryptamine (DMT) and 5-methoxy-N, N-dimethyltryptamine (5-MeO-DMT) show therapeutic potential for treatment-resistant psychiatric disorders including substance addictions.</p><p><strong>Methods: </strong>This systematic review and meta-analysis synthesized DMT intervention studies (1960-2024) across PubMed, PsycINFO, Web of Science, and EBSCO databases, calculating pooled effects for substance use reduction. Subgroup sensitivity analyses examined the impacts of psychotherapy, population type, and treatment design on outcomes.</p><p><strong>Results: </strong>DMT yielded a large overall effect size for substance abuse reduction (<i>g</i> = 0.94, 95% CI: 0.56-1.31, <i>p</i> < 0.0001), with superior efficacy for drug use (<i>g =</i> 1.35, 95% CI: 0.63-2.07, <i>p</i> < 0.0001) compared to alcohol use (<i>g</i> = 0.65, 95% CI: 0.31-0.99, <i>p</i> < 0.0001). Studies incorporating psychotherapy showed significantly greater effects (<i>g</i> = 1.38, 95% CI: 1.06-1.71, <i>p</i> < 0.0001) than those without (<i>g</i> = 0.60, 95% CI: 0.09-1.12, <i>p</i> < 0.0001), with significant subgroup difference (<i>p</i> = 0.0121). High risk of bias and high heterogeneity were observed (<i>I</i>² = 96.9%), with effects varying by substance type and treatment context. No publication bias was detected.</p><p><strong>Conclusion: </strong>When combined, available studies demonstrate DMT's potentially substantial post-treatment efficacy for substance misuse, particularly with psychotherapy. Effect magnitudes vary by abused substances. Included studies had substantial methodological limitations and high risk of bias. Reported effects should therefore be interpreted as preliminary rather than indicative of established efficacy. Furthermore, the use of exploratory subgroup analyses in this review can only conclude that DMT efficacy for treating alcohol and substance abuse disorders is highly heterogeneous, depending on study and treatment design. If sustained positive results are clearly demonstrated in future research, it might position DMT-assisted psychotherapy as an effective, economical alternative to conventional treatments.</p>","PeriodicalId":16892,"journal":{"name":"Journal of Psychopharmacology","volume":" ","pages":"2698811261430518"},"PeriodicalIF":5.5,"publicationDate":"2026-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147674505","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cannabidiol for psychotic disorders: A meta-analysis of randomized controlled trials.","authors":"Mattia Marchi, Karim Rachedi, Alessia Bof, Giulio Mele, Luca Pingani, Silvia Ferrari, Gian Maria Galeazzi","doi":"10.1177/02698811261430501","DOIUrl":"https://doi.org/10.1177/02698811261430501","url":null,"abstract":"<p><strong>Background: </strong>Cannabidiol (CBD) is being investigated as a novel antipsychotic treatment, but its effects on psychosis are mainly drawn from pre-clinical studies, leading to uncertainty about its clinical impact.</p><p><strong>Aims: </strong>To evaluate the efficacy and tolerability of CBD in patients with schizophrenia spectrum disorders.</p><p><strong>Methods: </strong>PubMed, Scopus, Embase, PsycInfo, Cumulative Index to Nursing and Allied Health Literature (CINAHL), and clinicaltrials.gov were searched up to July 2025. Randomized controlled trials (RCTs) of CBD in adults with schizophrenia spectrum disorders were included. Pairwise meta-analyses were conducted using random-effects models. The primary outcome was the standardized mean difference (SMD), with 95% confidence interval (95% CI), between CBD and controls at post-treatment on psychosis symptom severity. Tolerability assessment considered pooled odds ratio (OR, with 95% CI) of trial withdrawal and side effects across treatment groups.</p><p><strong>Results: </strong>A total of eight trials (six published and two unpublished), accounting for 288 participants diagnosed with psychotic disorders, were included. CBD was administered orally, at a median daily dose of 800 mg. Follow-up times ranged from 20 minutes to 12 weeks. Effect size for CBD on psychosis symptom severity was not statistically significant (SMD: -0.194; 95%CI: -0.444 to 0.056), similarly on cognitive, and psychosis positive and negative symptoms. Tolerability assessments were comparable across CBD and controls. Quality of the evidence ranged from low to very low.</p><p><strong>Conclusions: </strong>Despite the limited number of outcomes assessed at the current state of the evidence, CBD did not show a clear benefit for psychosis symptoms in RCTs but was generally well tolerated. Larger, high-quality trials are needed to reach more robust conclusions about CBD efficacy in these disorders.</p>","PeriodicalId":16892,"journal":{"name":"Journal of Psychopharmacology","volume":" ","pages":"2698811261430501"},"PeriodicalIF":5.5,"publicationDate":"2026-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147633724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nathan S. Kline: From the first treatments of psychosis and depression, a 70-year legacy of a pioneer of psychopharmacology.","authors":"Larissa Junkes, Richard I Shader, Antonio E Nardi","doi":"10.1177/02698811261436582","DOIUrl":"https://doi.org/10.1177/02698811261436582","url":null,"abstract":"<p><p>The current era is characterized by the pursuit of novel medications and drug repurposing through innovative mechanisms that modulate systems beyond the monoaminergic, focusing on novel synaptic signaling targets. Against this backdrop, it can be challenging to recall a time when psychopharmacology was in its infancy, and every discovery represented the cutting edge. Nathan S. Kline, a clinician and researcher, was a pivotal figure in introducing the first psychoactive substances into clinical practice. His seminal work on reserpine as a sedative and his evaluation of the antidepressant properties of iproniazid, a monoamine oxidase inhibitor (MAOI), positioned him at the scientific vanguard of pharmacological psychiatry. Kline made multiple substantial contributions to the medical-scientific literature, publishing foundational papers on the use of reserpine in neuropsychiatric hospitals, the application of <i>Rauwolfia serpentina</i> for neuropsychiatric conditions, and comparative studies of iproniazid and other MAOIs, among numerous other manuscripts. Kline's enduring legacy extends beyond psychopharmacology, encompassing early efforts in health informatics to optimize psychiatric logistics and advocacy for the expansion of global mental health care networks, including in low- and middle-income countries.</p>","PeriodicalId":16892,"journal":{"name":"Journal of Psychopharmacology","volume":" ","pages":"2698811261436582"},"PeriodicalIF":5.5,"publicationDate":"2026-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147628048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of antidepressant use on MDMA fatalities: A matched case-control study using a post-mortem database.","authors":"Kirsten L Rock, Paul Rees, David Morgan, Caroline S Copeland","doi":"10.1177/02698811261436573","DOIUrl":"https://doi.org/10.1177/02698811261436573","url":null,"abstract":"<p><strong>Background: </strong>3,4-methylenedioxymethamphetamine (MDMA) is being investigated as a new therapy for post-traumatic stress disorder (PTSD). With antidepressants as the first-line pharmacotherapy for PTSD, it is important to understand any drug-drug interactions between antidepressants and MDMA. This study aimed to investigate the association between antidepressant use and MDMA fatality using a drug-death database.</p><p><strong>Methods: </strong>A retrospective case-control study was performed using a dataset from the National Programme on Substance Use Mortality. Deaths reported between 1997 and May 2023 were extracted. Cases were defined as deaths with MDMA detected and were age- and sex-matched to controls, defined as deaths with no MDMA detected. Cases were analysed by post-mortem (PM) detection of antidepressants and prescription of antidepressants. Conditional logistic regression was performed, adjusted for confounders (polysubstance use and intentionality of death).</p><p><strong>Results: </strong>A total of 1328 cases and 5312 matched controls for the PM analysis and 840 cases and 3360 matched controls for the prescribed analysis were included. In the PM analysis, after adjusting for potential confounders, antidepressant use was less likely in MDMA fatalities compared to other drug-related deaths (adjusted OR [aOR] 0.595 [95% Confidence interval (CI) 0.491-0.722]). In the prescribed analysis, there was no significant association between the prescription of antidepressants and MDMA fatalities (aOR 0.838 [95% CI 0.688-1.021]).</p><p><strong>Conclusions: </strong>An inverse association was found between antidepressant use and MDMA fatality in this retrospective case-control study using a drug-death database.</p>","PeriodicalId":16892,"journal":{"name":"Journal of Psychopharmacology","volume":" ","pages":"2698811261436573"},"PeriodicalIF":5.5,"publicationDate":"2026-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147627092","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antipsychotic action and symptom specificity - down the bioinformatic rabbit hole.","authors":"Gavin P Reynolds","doi":"10.1177/02698811261436575","DOIUrl":"https://doi.org/10.1177/02698811261436575","url":null,"abstract":"","PeriodicalId":16892,"journal":{"name":"Journal of Psychopharmacology","volume":" ","pages":"2698811261436575"},"PeriodicalIF":5.5,"publicationDate":"2026-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147609243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The unique efficacy of clozapine is attributable to muscarinic receptor agonism.","authors":"Paul D Morrison, Robin M Murray, Sameer Jauhar, Allan H Young","doi":"10.1177/02698811261436585","DOIUrl":"https://doi.org/10.1177/02698811261436585","url":null,"abstract":"<p><p>Clozapine is superior to all other antipsychotic drugs for treatment-resistant schizophrenia, but the molecular underpinnings for this have remained elusive for decades. Recently, we proposed a cholinergic mechanism, based on the distinct pharmacology of clozapine in the parasympathetic branch of the autonomic nervous system, a hypothesis strengthened by the translation of a new cholinergic-based antipsychotic drug into clinical practice. A recent article has challenged the cholinergic hypothesis and instead proposed a mechanism involving the action of clozapine at noradrenaline receptors of the α₂ class. We consider that this hypothesis is implausible for two reasons. Firstly, numerous antipsychotics that are inferior to clozapine act at α₂ noradrenergic receptors, in an identical manner to clozapine. Moreover, there is no evidence that α₂ noradrenergic antagonists have any antipsychotic effects in the clinic. A clear difference between clozapine and the other, less efficacious antipsychotics is its ability to behave as an agonist at acetylcholine receptors of the muscarinic class. In the striatum, acetylcholine and dopamine are vital signals for salience and neuroplasticity. Dopamine (D₂) antagonism and acetylcholine (muscarinic M₁/M₄) agonism carry an antipsychotic signature. Clozapine may have the ideal properties of low-potency dopamine D₂ binding, allied with partial agonism at muscarinic M₁ and M₄ receptors.</p>","PeriodicalId":16892,"journal":{"name":"Journal of Psychopharmacology","volume":" ","pages":"2698811261436585"},"PeriodicalIF":5.5,"publicationDate":"2026-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147592767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The behavioural effects of the serotonin 1A receptor agonist buspirone on reward processing in healthy volunteers: A randomised, placebo-controlled study.","authors":"Alexander L W Smith, Sorcha Hamilton, Susannah E Murphy, Philip J Cowen, Catherine J Harmer","doi":"10.1177/02698811261430527","DOIUrl":"https://doi.org/10.1177/02698811261430527","url":null,"abstract":"<p><strong>Background: </strong>The 5-HT_1A receptor is widely expressed throughout the brain and is implicated in reward processing; however, the acute effects of 5-HT_1A receptor agonism on reward and aversive processing in humans remain unclear.</p><p><strong>Aims: </strong>We investigate whether acute 5-HT_1A receptor agonism influences various stages of reward and aversive processing, specifically consummation, motivation and learning.</p><p><strong>Methods: </strong>In a double-blind, placebo-controlled study using a single 20 mg dose of buspirone, a serotonin 5-HT_1A receptor partial agonist, 62 healthy volunteers underwent 3 tasks: a taste task, an effort-expenditure decision task and a probabilistic instrumental learning task (PILT).</p><p><strong>Results: </strong>In healthy volunteers, acute buspirone increases the aversiveness of bitter tastes, non-significantly reduces willingness to exert effort and increases optimal choice during loss trials in the PILT.</p><p><strong>Conclusions: </strong>Speculatively, this could indicate that acute 5-HT_1A agonism may worsen several stages of aversive processing, with minimal effect on reward processing. The study was pre-registered (clinicaltrials.gov, Serotonin-receptor Agonism in Reward Processing, NCT05357547).</p>","PeriodicalId":16892,"journal":{"name":"Journal of Psychopharmacology","volume":" ","pages":"2698811261430527"},"PeriodicalIF":5.5,"publicationDate":"2026-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147574382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Administration of an extrasynaptic δ-subunit GABA_A receptor agonist in the prelimbic cortex attenuates methamphetamine sensitisation and relapse to methamphetamine-seeking behaviour in male rats.","authors":"Maarten van den Buuse, Jessica Roberts, Michael T C Hunter, Gracie L Hay, Nicholas A Everett, Sarah J Baracz, Travis A Wearne, Jennifer L Cornish","doi":"10.1177/02698811261430509","DOIUrl":"https://doi.org/10.1177/02698811261430509","url":null,"abstract":"<p><strong>Aims: </strong>Chronic methamphetamine (METH) intake is associated with a high risk of psychosis and high susceptibility to relapse following abstinence. Prelimbic cortex (PLC) extrasynaptic GABA_A receptors containing the δ-subunit may be involved in the long-term effects of METH. We therefore investigated the effects of intra-PLC injection of the δ-subunit GABA_A receptor agonist 4,5,6,7-tetrahydroisoxazolo (5,4-c)pyridine-3(-ol) (THIP), on METH sensitisation, a model of METH psychosis, or relapse to METH seeking behaviour following extinction of intravenous self-administration.</p><p><strong>Methods and results: </strong>In Experiment 1, male rats received 1 week of chronic treatment with METH (1 mg/kg days 1 and 7, 5 mg/kg days 2-6) or saline, followed by 14 days withdrawal. THIP (0, 0.1, 0.3 or 1.0 μg per hemisphere) was then micro-injected into the PLC prior to challenge with METH (1 mg/kg) or saline. Acute METH challenge enhanced locomotor hyperactivity in METH-pretreated rats, confirming sensitisation. THIP administration into the PLC dose-dependently reduced the effect of acute METH challenge in METH-pretreated rats. In Experiment 2, rats were trained to intravenously self-administer METH, followed by 2 weeks of extinction. Rats were then given a METH priming injection or exposed to cues associated with METH self-administration, both of which reinstated responding on the lever previously paired with METH delivery. At the 0.3 µg dose, injection of THIP into the PLC reduced reinstatement responding in both paradigms.</p><p><strong>Conclusion: </strong>Selective activation of extrasynaptic PLC δ-subunit GABA_A receptors reduced METH sensitisation and drug primed or cue-induced METH-seeking behaviour. These findings may aid development of effective pharmacotherapies for treating chronic METH use.</p>","PeriodicalId":16892,"journal":{"name":"Journal of Psychopharmacology","volume":" ","pages":"2698811261430509"},"PeriodicalIF":5.5,"publicationDate":"2026-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147574386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}